Ask your doctor if this non-invasive stimulation of the vagus nerve would be better. I don't care that this wasn't tested in stroke yet. Does no one have any brains to rub two neurons together to run this non-invasive one thru stroke clinical trials?
FDA Releases gammaCore®, the First Non-Invasive Vagus Nerve Stimulation Therapy Applied at the Neck for Acute Treatment of Pain Associated with Episodic Cluster Headache in Adult Patients
http://www.marketwired.com/press-release/microtransponder-presents-long-term-stroke-trial-data-ins-announces-120-patient-pivotal-2219173.htm
Late Breaking Long Term Clinical Study Results at the International Neuromodulation Society Conference Show Continued Improvement for Stroke Patients and a New 120 Patient Stroke Trial Will Begin Enrollment this Summer
DALLAS, TX--(Marketwired - May 30, 2017) - MicroTransponder, Inc., (www.microtransponder.com)
today unveiled new positive long-term positive clinical trial results
from the Vivistim™ Stroke Rehabilitation trial. The objective of this
multicenter, double-blind, randomized, active-controlled trial was to
improve upper limb mobility in stroke survivors suffering chronic
disability. The data was presented by Jesse Dawson M.D., University of
Glasgow Hospital, and Teresa Kimberley, PhD, University of Minnesota
Hospital. They presented the data to the clinicians gathered at the
International Neuromodulation Society (INS) conference in Edinburgh, UK.
The data showed 75% of patients had a clinically meaningful response on
the Fugl-Meyer Upper Extremity Scale (FMUE) at the end of a six weeks
of physical therapy compared to 33% for the control group. 90 days after
the six weeks of physical therapy ended 88% of VNS patients had
responded compared to 33% in the control arm. And during the long-term
portion of the study average FMUE scores continued to increase, with the
6 month and 9 month data showing further gains. All responders
indicated they believed their overall health had improved and were
satisfied with the therapy.
"We saw remarkable improvement in some patients' upper limb function over the course of this trial," said Dr. Dawson. "For many patients, this included important daily activities such as feeding, grooming, driving, and dressing themselves. Some patients were able to resume their higher-level hobbies, such as photography, practicing piano, hosting large family events, and playing golf. Overall, my patients were able to integrate the at- home-therapy component of the program quite easily into their lives."
The Stroke Rehabilitation trial featured the Vivistim® System, which is a neurostimulation based system with a small implanted battery and wires that internally connect to the vagus nerve in the neck. As the patient performs physical therapy exercises, they receive a small burst of neurostimulation to their vagus nerve. This Paired VNS® (Vagus Nerve Stimulation) method is based on decades of neuroscience research and takes advantage of the brain's ability to rewire itself (neuroplasticity). When stimulated, the vagus nerve causes the release of neurochemicals in the brain that encourage neuroplasticity. More information can be found on www.MicroTransponder.com.
In addition to the presentation of the long-term data, Frank McEachern, CEO of MicroTransponder; also spoke at the INS. McEachern announced that MicroTransponder had received IDE approval from the FDA to run a 120-patient pivotal trial. The stroke rehabilitation trial will include 12 U.S. and 3 UK centers and will begin enrolling patients this Summer. "There are currently very few options for chronic stroke survivors and our committed team of physicians, researchers, and engineers hope to deliver a meaningful option that will make a significant difference for these survivors and their families," noted McEachern. "We experienced an outpouring of interest from many academic centers to participate in our clinical trials once we presented our initial stroke rehabilitation data at the International Stroke Conference earlier this year. We are pleased to announce that our 120-patient clinical trial is now approved and includes many prestigious institutions and some of the best stroke and neurostimulation researchers worldwide. Enrollment will begin this Summer and additional clinical trial information can be found by visiting www.vnsstroketrial.com."
About MicroTransponder, Inc.
MicroTransponder Inc. (www.microtransponder.com) is a medical device development company with a strong neuroscience research focus. An experienced team of scientists and engineers has developed neurostimulation technology platforms to treat various forms of neurological diseases, including post stroke motor rehabilitation and tinnitus. MicroTransponder has a sizeable neurostimulation-focused R&D program which is able to quickly translate scientific discoveries into clinical therapies.
"We saw remarkable improvement in some patients' upper limb function over the course of this trial," said Dr. Dawson. "For many patients, this included important daily activities such as feeding, grooming, driving, and dressing themselves. Some patients were able to resume their higher-level hobbies, such as photography, practicing piano, hosting large family events, and playing golf. Overall, my patients were able to integrate the at- home-therapy component of the program quite easily into their lives."
The Stroke Rehabilitation trial featured the Vivistim® System, which is a neurostimulation based system with a small implanted battery and wires that internally connect to the vagus nerve in the neck. As the patient performs physical therapy exercises, they receive a small burst of neurostimulation to their vagus nerve. This Paired VNS® (Vagus Nerve Stimulation) method is based on decades of neuroscience research and takes advantage of the brain's ability to rewire itself (neuroplasticity). When stimulated, the vagus nerve causes the release of neurochemicals in the brain that encourage neuroplasticity. More information can be found on www.MicroTransponder.com.
In addition to the presentation of the long-term data, Frank McEachern, CEO of MicroTransponder; also spoke at the INS. McEachern announced that MicroTransponder had received IDE approval from the FDA to run a 120-patient pivotal trial. The stroke rehabilitation trial will include 12 U.S. and 3 UK centers and will begin enrolling patients this Summer. "There are currently very few options for chronic stroke survivors and our committed team of physicians, researchers, and engineers hope to deliver a meaningful option that will make a significant difference for these survivors and their families," noted McEachern. "We experienced an outpouring of interest from many academic centers to participate in our clinical trials once we presented our initial stroke rehabilitation data at the International Stroke Conference earlier this year. We are pleased to announce that our 120-patient clinical trial is now approved and includes many prestigious institutions and some of the best stroke and neurostimulation researchers worldwide. Enrollment will begin this Summer and additional clinical trial information can be found by visiting www.vnsstroketrial.com."
About MicroTransponder, Inc.
MicroTransponder Inc. (www.microtransponder.com) is a medical device development company with a strong neuroscience research focus. An experienced team of scientists and engineers has developed neurostimulation technology platforms to treat various forms of neurological diseases, including post stroke motor rehabilitation and tinnitus. MicroTransponder has a sizeable neurostimulation-focused R&D program which is able to quickly translate scientific discoveries into clinical therapies.
No comments:
Post a Comment